Pilot study: Rapamycin in advanced hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 6, 2010, Pages 763-768

  Schöniger Hekele, Maximilian ^a   Müller, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; RAPAMYCIN; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BACTERIAL PERITONITIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EDEMA; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPOKALEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PILOT STUDY; PRIORITY JOURNAL; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; SIROLIMUS; TREATMENT OUTCOME;

EID: 77955743591     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04404.x     Document Type: Article

References (27)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 : 2557 2576.
2. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999 19 : 329 338.
3. Giannini EG, Bodini G, Corbo M, et al. Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 2010 4 : 493 501.
4. Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002 224 : 47 54.
5. Myers RP. Meta-analysis of transarterial embolization in patients with unresectable hepatocellular carcinoma. Radiology 2003 227 : 611 612 author reply 612-3.
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 4 : 378 390.
7. Chaparro M, González M, Trapero-Marugán M, Medina J, Moreno-Otero R. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 2008 28 : 1269 1277.
8. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010 31 : 461 476.
9. Sehgal SN, Molnar-Kimber K, Ocain TD, et al. Rapamycin: a novel immunosuppressive macrolide. Med Res Rev 1994 14 : 1 22.
10. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Invest Drugs 2002 3 : 295 304.
11. Huang S, Houghton PJ. Resistance to rapamycine: a novel anti-cancer drug. Cancer Metastasis Rev 2001 20 : 69 78.
12. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 5-year experience. Transplant Proc 2003 35 : 52S 7S.
13. Radovancevic B, Vrtovec B. Sirolimus therapy in cardiac transplantation. Transplant Proc 2003 35 : 171S 6S.
14. Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003 35 : 193S 200S.
15. Jefferies HB, Fumagalli S, Dennis BP, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 1997 16 : 3693 3704.
16. Terada N, Patel HR, Takase K, Kohno K, Nairn AC, Gelfand EW. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci U S A 1994 91 : 11477 11481.
17. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008 135 : 1972 1983. e1-11.
18. Newell P, Toffanin S, Villanueva A, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009 51 : 725 733.
19. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001 35 : 421 430.
20. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 1236.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 : 205 216.
22. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008 100 : 698 711.
23. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004 10 : 1301 1311.
24. Zhou J, Fan J, Wang Z, et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: report of an initial experience. World J Gastroenterol 2006 12 : 3114 3118.
25. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J. Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 2005 79 : 855 857.
26. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010 51 : 1237 1243.
27. Andrassy J, Graeb C, Rentsch M, Jauch KW, Guba M. mTOR inhibition and its effect on cancer in transplantation. Transplantation 2005 80 (1 Suppl. S171 4.